For the study, a team led by Dr. Adriano Chiò University of Turin in
They found little difference in the health of those taking the high dosage of lithium. The trial was stopped early in November 2009 because 68 percent of the test group had died.
"This discontinuation rate is two times higher than that in other recent studies for ALS drugs," Chiò told Science Daily. "This high dropout level, along with the relatively high frequency of side effects, raises serious doubts about the safety of this drug and also shows it to be ineffective for people with ALS."
by RTT Staff Writer
For comments and feedback: contact editorial@rttnews.com
No comments:
Post a Comment